Tirzepatide verlaagt cardiovasculaire risico's en sterfte meer dan semaglutide bij diabetes type 2

PURPOSE: tirzepatide is associated with greater glycemic control and weight reduction compared to semaglutide in patients with T2D. Tirzepatide has also been recently shown to be non-inferior to dulaglutide in cardiovascular risk reduction among patients with T2D. Whether tirzepatide is more or less effective than semaglutide for cardioprotection is underexplored. METHODS: The Research Collaborative Network of the TriNetX platform was accessed to collect de-identified, real world data on patients with T2D and compare the incidence of a composite of cardiovascular outcomes including acute myocardial infarction, stroke and acute heart failure, as well as all-cause mortality between patients who used tirzepatide and patients who used semaglutide during the period May 13, 2022 to Aug 11, 2026. One-to-one propensity score matching was applied to control for possible confounding covariates. RESULTS: two well-matched cohorts (N = 271,685 for each) were analyzed. Compared to the semaglutide group, the tirzepatide group had lower incidences of the primary composite outcome (4.6% vs. 5.5%; absolute risk difference [ARD] -0.9%, 95% confidence interval [CI] -1.01 to -0.77; hazard ratio [HR] 0.9, 95% CI 0.92─0.96) and all-cause mortality (0.6% vs. 0.9%; ARD - 0.3%, 95% CI -0.33 to -0.24; HR 0.8, 95% CI 0.74─0.84). CONCLUSION: Tirzepatide was associated with lower risk of a composite of outcome of cardiovascular events as well as all-cause mortality compared to semaglutide in patients with T2D. CLINICAL TRIAL REGISTRATION: Clinical trial number: not applicable. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at https://doi.org/10.1007/s40200-026-02087-z.